The reason they "bother accepting such a late report" is because that's how good science works.
A quick look at the 2017 AHA conference in Anaheim shows that the results of a trial have zero bearing on the decision to be included in late breaking sessions. For example, the ALLSTAR (Intracoronary ALLogenic Heart STem Cells to Achieve Myocardial Regeneration) Phase II trial was a 2017 late breaking session and the conclusion was that there were similar results between the treatment group and placebo group.
IMHO(fwiw) the short position has increased significantly in the last months as they are hoping for an ambivalent result next week and perhaps the above example is guiding their thinking - I hope they have misread the situation, we will see next week when all is revealed.
Until then second guessing is just guessing ……...
GLTAH
All Aboard, page-8
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |